Background/Objectives: Mycosis fungoides (MF) in young patients is rare and may have atypical presentations. There are limited data in these patients. The objective was to determine the clinical outcome and prognosis of young patients with MF. Methods: A search of our institutional cancer registry database was conducted for patients diagnosed with MF at younger than 30 years of age. Results: Our study included 74 patients (median age at diagnosis 25.5 yrs). Sixty-five (88%) presented with early stage disease and variants of MF (n = 44 [59%]), leading to a median delay in diagnosis of 2.5 years. Hypopigmented MF (n = 27 [36.5%]) was the most common variant, affecting predominantly African American (44.4% vs 19%; p = 0.02) and younger (20 vs 26 yrs; p < 0.001) patients. All patients with hypopigmented MF presented with early stage disease and were less likely to develop progressive disease (PD) than those with other variants (11% vs 34%; p = 0.03). Nineteen patients (26%) developed PD during a median follow-up of 3.5 years, which was associated with advanced-stage disease (89% vs 17%; p < 0.001), older age (>20 yrs) (31% vs 13%; p = 0.08), African American race (52.6% vs 20%; p = 0.009), and poikilodermatous presentation (p < 0.01). Overall survival was good (97.2% at 5 yrs, 95.9% at 10 yrs) despite the delay in diagnosis and atypical presentation. Conclusions: Progressive disease is associated with older age, African American race, the poikilodermatous variant, and advanced-stage disease.
The hypopigmented variant is a common presentation in young patients and has an indolent disease course. Our study confirms an overall favorable prognosis in young patients with MF.
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL) (1) . It typically affects older adults, with the majority of patients diagnosed after 50 years of age (2) . Although the survival of patients diagnosed with early stage disease is similar to that of age-matched controls, patients diagnosed with advanced disease (≥ stage IIB) have a median survival ranging from 17 months to 4.7 years (3, 4) . Primary CTCL is rare in children. In the United States, only 14 cases of CTCL in children younger than 9 years of age and 33 cases in those 10 to 19 years of age were reported to cancer registries between 1973 and 2002, resulting in age-adjusted incidence levels of 0.1 and 0.3 per 1,000,000 persons-years, respectively (5) . In a Surveillance Epidemiology and End Results (SEER) population-based study, the incidence of MF/ S ezary syndrome (SS) was reported as 0.3 per 1,000,000 person-years for patients younger than 20 years of age and 1.0 per 1,000,000 person-years for patients between 20 and 29 years of age (6) . In a recent study by Kempf et al (7) , MF was reported as one of the most prevalent cutaneous lymphomas in children. The diagnosis of MF may be delayed in young patients because of its low incidence and varied clinical presentation, as well as physician reluctance to perform skin biopsies in younger individuals (8, 9) .
Retrospective studies suggest that the prognosis of MF in young patients is more favorable than in adults, but there are no large studies that define the disease course and long-term outcomes in young patients (10, 11) . Based on the large SEER population study (6) , we decided to use 30 years as the cutoff age for our study. In this study, our objective was to analyze clinical features, disease course, risk of disease progression, and overall survival of a cohort of patients diagnosed with MF at a young age.
METHODS
Following approval by the Institutional Review Board at Memorial Sloan Kettering Cancer Center (MSKCC), a search of the cancer registry database at our institute was conducted. International Classification of Diseases for Oncology histology codes for MF (M9700), pathology key words (mycosis fungoides, cutaneous T-cell lymphoma, parapsoriasis) and age at tumor diagnosis date (≤30 yrs) were the search terms specified. All cases retrieved from the time of the database creation in 1990 to the date of search in March 2015 were reviewed.
After identification of 171 unique potential patients, we reviewed the charts and pathology of all patients for inclusion and exclusion criteria. Patients with clinically and histopathologically confirmed MF were selected. Our inclusion criteria included diagnosis at 30 years of age or less, clinical diagnosis of "mycosis fungoides" and histology "consistent with," "compatible with," or "most in keeping with" MF, as well as the presence of an "atypical epidermotropic lymphocytic infiltrate" with positive clonality. Exclusion criteria included patients who never saw a dermatologist at MSKCC or did not receive histopathologic confirmation of MF from a dermatopathologist at MSKCC. Pathology reports described as "possible MF," "probable MF," "suspicious for MF," "worrisome for MF," and "not unequivocal for MF" were excluded. In total, 97 patients were excluded, resulting in 74 patients who were included in the study.
A retrospective chart review was performed for each patient using the electronic medical record. Data gathered included demographic variables (age, sex, race, date of birth, date of reported onset of rash, date of initial diagnosis); past medical history (presence of comorbidities, specifically, asthma, eczema, and other lymphoma or lymphoproliferative disorders); family history of lymphoma or leukemia; physical examination findings at presentation and follow-up visits, including lymph node and organomegaly status; disease stage at presentation; and treatments and types and dates of response. Complete remission was defined as complete resolution of cutaneous and extracutaneous disease. Partial remission was defined as 50% or more resolution of cutaneous or extracutaneous disease. Stable disease was defined as less than 50% response with no evidence of disease progression. Progressive disease (PD) was defined as a greater than 25% increase in skin disease from baseline, development of new tumors, or an increase in disease stage. Relapse was defined as recurrence of disease after complete remission. Disease course and treatment responses were recorded from clinical encounters with the cutaneous lymphoma experts at our institute and from images taken at each follow-up visit.
Statistical Analysis
All descriptive and comparative statistical analyses were performed using Stata software version 12.0 (StataCorp, College Station, TX). Descriptive analysis of the patients is summarized in Table 1 .
When exact dates (for initial diagnosis of MF, last follow-up visit, death) were not available, we used the first day of the month of occurrence or June 1 of the year of occurrence of the event, depending on how much information was available. Delay in diagnosis was calculated from the date of reported onset of rash to the date of initial diagnosis, whether at MSKCC or an outside institution. Overall survival was defined as the percentage of patients alive at the end of 5 and 10 years of follow-up. Total years of follow-up were calculated from the date of initial diagnosis of MF to the most recent clinic visit at the time of data collection or date of death.
RESULTS

Patient Characteristics
The median age at diagnosis was 25.5 years (range 6-30 yrs). Fifty-one (69%) patients were 21 to 30 years of age (median age 26.7 yrs) at the time of diagnosis and the remaining 23 (31%) were 20 years or younger (median age 17 yrs). The median age of reported onset of rash was 19 years (range 6-29 yrs) and the median delay in diagnosis was 2.5 years (range 0-28 yrs). Three patients presented at age 12 years or younger (two were younger than 10 years), with no reported delay in diagnosis. The median duration of follow-up was 3.5 years (range 1 mos-34 yrs) ( Table 1) .
Clinical Characteristics
Sixty-five (88%) patients presented with early stage MF (I-IIA) and the remaining nine (12%) with advanced-stage disease (IIB-IV). Both patients Clinically, patches were present in 37 (50%) patients, plaques in 22 (30%), papules in 8 (11%), ulcers in 2 (3%), and skintumorsin4 (5%). Lower extremities (81%) were most commonly involved, followed by the trunk (76%) and upper extremities (61%). The head and neck were involved in 12 (16%) patients.
Thirty patients (40.5%) presented with classic mildly erythematous, scaly patches and plaques, but the remaining 59.5% presented with nonclassic variants: 27 (36.5%) with hypopigmented, 6 (8.1%) with hyperpigmented, 4 (5.4%) with poikilodermatous, and 7 (9.5%) with folliculotropic MF. Hypopigmented MF was most commonly reported in African Americans (44.4%) and Asians (18.5%).
We compared the characteristics of patients with hypopigmented MF (n = 27 [36.5%]) with those of patients with nonhypopigmented MF (n = 47 [63.5%]) ( Table 2 ). The former MF patients were more likely to be African American (44.4% vs 19%; p = 0.02) and younger at diagnosis (20 vs 26 yrs; p < 0.001). All patients with hypopigmented MF presented with early stage MF (I-IIA) and 19% with non-hypopigmented MF had advanced stage disease at presentation (p = 0.01). At the last follow-up, 16 (34%) patients with nonhypopigmented MF and 3 (11%) with hypopigmented MF had evidence of PD (p = 0.03).
Histopathology
Patch and plaque lesions of MF were typically described with the characteristic epidermotropic + lymphocytes in all evaluated cases, but the epidermotropic infiltrates were found to be CD8 predominant in most cases of hypopigmented MF. T-cell receptor gene rearrangements were monoclonal in 38 (51%) cases. Thirteen (18%) cases were not evaluated using molecular techniques.
Disease Course and Outcome
Nineteen patients (26%) developed PD during followup. A higher percentage of those older than 20 years at diagnosis developed PD than of those 20 years of age and younger (31% vs 13%; p = 0.08) ( Table 3 ). African American patients had a higher risk of PD (p < 0.01) than others. Patient sex, family history of lymphoma, past medical history of other lymphoma or lymphoproliferative disorders, and other comorbidities were not significantly associated with disease progression.
All evaluated patients diagnosed with advanced MF (stage IIB-IV) (n = 8 [89%]) had evidence of PD during follow-up and 73% of patients with stage I/II disease had stable disease with good response to treatment. One of the patients with stage II MF was lost to follow-up after the initial consultation.
All four (100%) patients with poikilodermatous MF had PD (p < 0.01); three of these progressed to develop skin tumors (T3N0M0B0) or nodal or systemic disease (T4NXM0B0, T2N3M1B2) and the fourth had progression limited to the skin (T2N0M0B0).
Three of seven (42.8%) patients with folliculotropic MF (p = 0.25) progressed to advanced-stage (T3N0M0B0, T2N3M0B0, T4N2M1B1) disease and the remaining four had stable cutaneous disease (T1-2N0M0B0).
Overall survival of our cohort of 74 patients was 97.2% at 5 years and 95.9% at 10 years; four died. Three died at the ages of 28, 32, and 30 years from rapidly progressive MF/Sezary syndrome with systemic and blood involvement within 1, 2, and 8 years of diagnosis, respectively. All three had classic MF and were older than 20 years at diagnosis. A fourth patient died 11 years after MF diagnosis from complications of coexisting metastatic thymoma at the age of 38 years. limited lesions after initial complete remission that were controlled with topical steroid use. All patients with stage IV disease at presentation (n = 5 [6.7%]) underwent chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone; etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab; or doxorubicin, gemcitabine) as first-line treatment. Local radiation was used to treat skin tumors in two patients (2.7%). Five patients (6.8%) required treatment with systemic agents (methotrexate, bexarotene, mogamulizumab/anti-CCR-4) for rapidly progressive disease.
DISCUSSION
MF in young patients is rare and often misdiagnosed, leading to delays in diagnosis. This is partly because MF may clinically mimic benign rashes, particularly atopic dermatitis, eczema, pityriasis alba, or vitiligo. The clinical resemblance to other pediatric eruptions, low index of suspicion, and reluctance to biopsy led to a median delay in diagnosis of 2.5 years in our patients (12) . MF typically presents in the fifth and sixth decades of life but can present as early as the first decade; the youngest patient in our cohort was 6 years old at the time of diagnosis. An increasing incidence was seen with age but without any sex predominance, similar to a large population-based study (1) .
We noticed a higher occurrence of MF variants in our young population than in reported data on adults (13): 36.5% with hypopigmented, 8% with hyperpigmented, 5% with poikilodermatous, and 9.5% with folliculotropic MF. We compared the characteristics of patients with hypopigmented MF with those of the remaining group. All patients with hypopigmented MF presented with early stage disease (IA-IB), followed by an indolent disease course with a favorable response to phototherapy. It most commonly affected patients younger than 20 years and African American patients. Our results are similar to the findings of a large retrospective study of pediatric hypopigmented MF by Castano et al (14) , which found hypopigmented MF to be the most common variant (72.5%) in a group of 69 patients diagnosed before 21 years of age.
Our data showed an overall 5-year survival of 97% and 10-year survival of 96%. Disease progression was seen in 26% of our patients and 42% of these had advanced-stage disease at initial presentation. Age older than 20 years, advanced stage, and African American race were found to be independent risk factors for disease progression. In support of our findings, a retrospective analysis from 1987 to 2007 at M.D. Anderson Cancer Center showed that African American patients were more than twice as likely to be diagnosed before the age of 40 years as Caucasians (15) . A more recent analysis by Balagula et al (16) confirmed a greater incidence of early onset MF in African American women as compared with Caucasians, with a higher risk of disease progression and poorer prognosis.
In addition, all patients with poikilodermatous MF in our cohort showed disease progression. These data are in contrast to a previously published study that found that only 2 of 49 patients (4%) progressed (17) . This discrepancy may be due to a significantly older median age at presentation than in our study (44 vs 25.5 yrs), which suggests that younger patients with the poikilodermatous variant may have more aggressive disease than older patients, although it is difficult to extrapolate definitive conclusions given the limited number of patients with poikilodermatous MF in our group.
Treatment options and outcomes in young patients are not well defined. nbUVB therapy for early MF in children is one of the first-line treatments recommended because of its low side-effect profile (18, 19) . Skin-directed regimens, including topical steroids, phototherapy, and combinations thereof, were the most commonly used treatment regimens in our group, which reflects previously published data from other centers (14, 20) . Most patients responded favorably to these regimens. Cutaneous relapses were generally easily controlled with topical steroids or further phototherapy courses. Treatment with nbUVB was generally well tolerated, with occasional mild side effects such as pruritus and erythema.
Data from retrospective studies suggest that, despite relapses, the outcome of in children seems more favorable than in adults when monitored over median follow-up periods of 43 months to 12 years (11, 14, 18) . Our data showed similar favorable outcomes despite delays in diagnosis. Most patients presented with early stage disease that rarely developed into advanced-stage MF. Progression of disease was most commonly seen in patients with limited skin disease (IA) to development of more widespread cutaneous lesions (IB). Disease progression to advanced stages (IIB-IV) was associated with advanced disease at initial presentation and poikilodermatous and folliculotropic subtypes of MF.
One of the limitations of our study was that it was a single-center retrospective study. Because of the rarity of the disease in the pediatric population, we had few patients diagnosed with MF at younger than 10 years of age. Our study could benefit from collaboration with large centers across the United States to study this rare disease specifically in the younger population. We studied the clinical course and outcome of young patients with MF and did not review their histopathology, although we excluded cases in which pathologists at MSKCC did not confirm the diagnosis. It would also be useful to study the histopathologic aspects of the disease in correlation with disease course and outcome in young patients.
In summary, our study was a large, single institution-based study of clinical outcomes and prognosis of young patients with MF. It confirmed the overall favorable prognosis and outcome in young patients. nbUVB and topical steroids were the most commonly prescribed treatment options, with complete or partial responses achieved in most patients. Our patients with advanced-stage disease had worse prognosis and outcomes similar to reported outcomes in adult MF (4) , but large prospective case-control studies are needed to compare the clinical course and outcomes in young and older patients with MF.
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